| 0.0001 -0 (-50%) | 04-23 13:38 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.62 |
1-year : | 0.92 |
| Resists | First : | 0.53 |
Second : | 0.79 |
| Pivot price | 0.22 |
|||
| Supports | First : | 0.12 |
Second : | 0.1 |
| MAs | MA(5) : | 0.22 |
MA(20) : | 0.24 |
| MA(100) : | 0.5 |
MA(250) : | 1.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 10.8 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 3.38 | Low : | 0.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GNRS ] has closed below upper band by 48.5%. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.42 |
| Low: | 0.13 - 0.13 | 0.13 - 0.13 |
| Close: | 0.23 - 0.23 | 0.23 - 0.23 |
Greenrose Holding Company Inc., through its subsidiaries, engages in the production and sale of cannabis products. It engages in cultivating, processing, and packaging medical cannabis and derivative products. The company was founded in 2014 and is headquartered in Amityville, New York.
Mon, 08 Aug 2022
The Greenrose Holding Company appoints new chief financial officer, as well as a new director to its board - Proactive Investors
Fri, 05 Aug 2022
The Greenrose Holding Company Announces New Leadership Appointments - Investing News Network
Mon, 03 Jan 2022
Greenrose Closes $57.6 Million Acquisition of Arizona Operator True Harvest - New Cannabis Ventures
Mon, 29 Nov 2021
Greenrose Acquisition renamed as The Greenrose Holding Company after closing of business combination with Theraplant - Proactive financial news
Mon, 29 Nov 2021
Greenrose Acquisition Corp. Announces Closing of Business Combination with Theraplant - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 18 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 71.7 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 291 (K) |
| Shares Short P.Month | 131 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 47.3 % |
| Operating Margin | -146 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | 346.2 % |
| Qtrly Rev. Growth | 25.8 % |
| Gross Profit (p.s.) | 1.05 |
| Sales Per Share | 1.6 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -4.58 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0.14 |
| Price to Cash Flow | -0.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|